Xenoport Inc. (XNPT) announced favorable preliminary results from a Phase 1 clinical trial after the close Thursday. The study was designed to assess the pharmacokinetics, safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate. The stock is now up 0.33 on 6K shares.
Xenoport declined during the first 2 hours of trade Thursday and finished down by 0.15 at $11.15. The stock closed near the middle of a 2 1/2 week range.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.